A newly finalized federal framework aims to close a longstanding gap in what is known about how approved medications affect pregnant women and their developing babies — with direct benefits for expectant families and their healthcare providers.

On May 8, 2026, the FDA issued final guidance titled Postapproval Pregnancy Safety Studies, establishing clear recommendations for how pharmaceutical companies should study the safety of their drugs and biological products in pregnant patients after those products reach the market. It is a significant development, one that addresses a gap that has existed in maternal healthcare for generations and has long frustrated both patients and providers.

The reason that gap exists comes down to history. Pregnant women have long been excluded from pre-approval clinical trials out of concern for fetal safety. That means by the time many medications are approved and available to the public, the data on how they specifically affect pregnancy is either very limited or entirely absent. Doctors are then left to make judgment calls based on incomplete information, carefully weighing uncertain risks against real and pressing medical needs. With around 3.6 million births taking place in the United States each year, and a significant number of pregnancies being unplanned, many patients end up taking medications during pregnancy without adequate safety data to guide those decisions.

The new guidance outlines specific research methods that drugmakers should use to fill those knowledge gaps after a product is already on the market. These include pregnancy registries, which track health outcomes in women who take a medication during pregnancy, real-world data studies that draw on large existing health databases, and analyses of individual case reports. Each of these approaches is designed to generate the kind of reliable human safety data that can eventually be translated into clearer, more accurate information on product labels under the Pregnancy section, giving both providers and patients better tools for making informed treatment decisions.

The guidance is particularly relevant to expectant parents who are managing ongoing health conditions like autoimmune disorders, epilepsy, mental health conditions, or chronic infections that may require continued medication during pregnancy. It is also directly relevant to pediatric healthcare providers who regularly counsel pregnant patients or new mothers about what is safe to take before and after birth.

For families, the impact of this guidance will not be immediate, but over time it should lead to more honest and complete conversations between patients and their doctors. Better data means better labeling, and better labeling means safer outcomes for pregnant patients and their newborns. In the meantime, any expectant parent with questions about medication safety during pregnancy should speak openly with their OB-GYN or pediatrician before making any changes to their treatment plan.

References / Sources

  1. U.S. Food and Drug Administration. FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics. Press Release, May 8, 2026. FDA.gov.
  2. National Institutes of Health, Office of Research on Women’s Health. Pregnant Women in Clinical Research. ORWH.od.nih.gov.

American College of Obstetricians and Gynecologists. Medications and Pregnancy. ACOG.org.